Nanobiotix SA

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

23 May 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

22 May 2024 01:00:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

21 May 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

16 May 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

15 May 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

14 May 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

24 Apr 2024 15:40:39 By Nasdaq GlobeNewswire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

17 Apr 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

10 Apr 2024 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

02 Apr 2024 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Present at Upcoming Investor Conferences in March

06 Mar 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Feb 2024 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

31 Jan 2024 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

29 Jan 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Jan 2024 15:32:08 By Nasdaq GlobeNewswire

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

26 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Dec 2023 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

04 Dec 2023 15:16:59 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

13 Nov 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

09 Nov 2023 15:15:00 By Nasdaq GlobeNewswire